Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Merck
Daiichi Sankyo
McKinsey
Citi
Julphar

Generated: July 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,989,474

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,989,474 protect, and when does it expire?

Patent 7,989,474 protects OFEV and is included in one NDA.

This patent has twelve patent family members in eleven countries.

Summary for Patent: 7,989,474
Title:Use of Lck inhibitors for treatment of immunologic diseases
Abstract: The invention relates to a method of treating immunologic diseases or pathological conditions involving an immunologic component using certain Lck inhibitors already known as kinase inhibitors for therapy in oncology, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives, pharmaceutical compositions comprising said Lck inhibitors together with said other drugs, and the use of the Lck inhibitors for the manufacture of a pharmaceutical composition for the treatment of immunologic diseases or pathological conditions involving an immunologic component.
Inventor(s): Roth; Gerald Juergen (Biberach, DE), Heckel; Armin (Biberach, DE), Walter; Rainer (Biberach, DE), Hilberg; Frank (Vienna, AT), Hauptmann; Rudolf (Ebreichsdorf, AT), Stefanic; Martin Fredrich (Warthausen-Birkenhard, DE), Colbatzky; Florian (Stafflangen, DE), Ernest; Steffan (Moelnlycke, SE)
Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim am Rhein, DE)
Application Number:12/334,323
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,989,474
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Drugs Protected by US Patent 7,989,474

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Boehringer Ingelheim OFEV nintedanib esylate CAPSULE;ORAL 205832-001 Oct 15, 2014 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (IPF) ➤ Try a Free Trial
Boehringer Ingelheim OFEV nintedanib esylate CAPSULE;ORAL 205832-002 Oct 15, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (IPF) ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,989,474

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany102 37 423Aug 16, 2002

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Deloitte
Chubb
UBS
Accenture
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.